Clinical and electroencephalographic assessment of diazepam in liver disease.
The effects of 5 mg of diazepam intravenously were assessed in 23 patients with liver disease, 10 of whom had clinical evidence either in the past or at the time of study of hepatic encephalopathy. Transient drowsiness occurred in all patients, but prolonged deterioration in conscious level was not observed. Serial electroencephalographic recordings showed the development of activity at faster frequencies, similar to that found in normal subjects, a change which is different from that usually observed in cirrhotic patients after administration of chlorpromazine and morphine when slow-wave activity is increased.
D000437:Alcoholism; D006502:Budd-Chiari Syndrome; D002779:Cholestasis; D002908:Chronic Disease; D003243:Consciousness; D003975:Diazepam / Q000627:therapeutic use*; D004569:Electroencephalography; D006501:Hepatic Encephalopathy / Q000188:drug therapy*; D006505:Hepatitis; D006801:Humans; D007275:Injections, Intravenous; D008103:Liver Cirrhosis; D008107:Liver Diseases; D008113:Liver Neoplasms
D003975:Diazepam